112 related articles for article (PubMed ID: 11786660)
1. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer.
Sakamoto M; Mikasa K; Majima T; Hamada K; Konishi M; Maeda K; Kita E; Narita N
Chemotherapy; 2001 Dec; 47(6):444-51. PubMed ID: 11786660
[TBL] [Abstract][Full Text] [Related]
2. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.
Mikasa K; Sawaki M; Kita E; Hamada K; Teramoto S; Sakamoto M; Maeda K; Konishi M; Narita N
Chemotherapy; 1997; 43(4):288-96. PubMed ID: 9209786
[TBL] [Abstract][Full Text] [Related]
3. [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer].
Sakamoto M; Mikasa K; Hamada K; Konishi M; Maeda K; Yoshimoto E; Ueda K; Majima T; Sawaki M; Kita E; Narita N
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2259-66. PubMed ID: 9881083
[TBL] [Abstract][Full Text] [Related]
4. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients.
Kayacan O; Karnak D; Beder S; Güllü E; Tutkak H; Senler FC; Köksal D
Am J Clin Oncol; 2006 Aug; 29(4):328-35. PubMed ID: 16891858
[TBL] [Abstract][Full Text] [Related]
5. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.
Awan S; Crosby V; Potter V; Hennig I; Baldwin D; Ndlovu M; Paradine S; Wilcock A
Lung Cancer; 2017 Feb; 104():75-78. PubMed ID: 28213005
[TBL] [Abstract][Full Text] [Related]
6. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
7. [Cytokines in experimental cancer cachexia].
Niu Q; Li T; Liu A
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):382-4. PubMed ID: 11810767
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.
Ando K; Takahashi F; Kato M; Kaneko N; Doi T; Ohe Y; Koizumi F; Nishio K; Takahashi K
PLoS One; 2014; 9(7):e102436. PubMed ID: 25010770
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.
Agteresch HJ; Dagnelie PC; van der Gaast A; Stijnen T; Wilson JH
J Natl Cancer Inst; 2000 Feb; 92(4):321-8. PubMed ID: 10675381
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
13. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
14. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
[TBL] [Abstract][Full Text] [Related]
15. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
[TBL] [Abstract][Full Text] [Related]
16. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience.
Henkenberens C; Janssen S; Lavae-Mokhtari M; Leni K; Meyer A; Christiansen H; Bremer M; Dickgreber N
Radiat Oncol; 2016 Feb; 11():12. PubMed ID: 26830686
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.
Greco FA; Stroup SL; Gray JR; Hainsworth JD
J Clin Oncol; 1996 May; 14(5):1642-8. PubMed ID: 8622083
[TBL] [Abstract][Full Text] [Related]
18. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer.
Hamada K; Mikasa K; Yunou Y; Kurioka T; Majima T; Narita N; Kita E
Chemotherapy; 2000; 46(1):49-61. PubMed ID: 10601798
[TBL] [Abstract][Full Text] [Related]
20. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
